ENTRADA THERAPEUTICS, INC. Revenue Breakdown
No Revenue Breakdown for TRDA on this site yet.
- 2025-12-31: Others Not split by product in the filing$25.42M100.00%; Total revenue $25.42M.
- 2024-12-31: Others Not split by product in the filing$210.78M100.00%; Total revenue $210.78M.
- 2023-12-31: Others Not split by product in the filing$129.01M100.00%; Total revenue $129.01M.
Source checked: the stored Revenue Breakdown page for TRDA.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $25.42M 100.00% | $25.42M |
| 2024-12-31 | Not split by product in the filing $210.78M 100.00% | $210.78M |
| 2023-12-31 | Not split by product in the filing $129.01M 100.00% | $129.01M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $898.00K 100.00% | $898.00K |
| 2026-03-31 | Not split by product $875.00K 100.00% | $875.00K |
| 2025-12-31 | Not split by product $1.30M 100.00% | $1.30M |
| 2025-09-30 | Not split by product $1.61M 100.00% | $1.61M |
| 2025-06-30 | Not split by product $1.95M 100.00% | $1.95M |
| 2025-03-31 | Not split by product $20.56M 100.00% | $20.56M |
| 2024-12-31 | Not split by product $37.40M 100.00% | $37.40M |
| 2024-09-30 | Not split by product $19.57M 100.00% | $19.57M |
| 2024-06-30 | Not split by product $94.69M 100.00% | $94.69M |
| 2024-03-31 | Not split by product $59.12M 100.00% | $59.12M |
| 2023-12-31 | Not split by product $41.85M 100.00% | $41.85M |
| 2023-09-30 | Not split by product $43.73M 100.00% | $43.73M |
| 2023-06-30 | Not split by product $18.17M 100.00% | $18.17M |
| 2023-03-31 | Not split by product $25.26M 100.00% | $25.26M |
| 2022-09-30 | Not split by product $0.00 | $0.00 |
| 2022-06-30 | Not split by product $0.00 | $0.00 |
| 2022-03-31 | Not split by product $0.00 | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |